A phase 2, multicentre, randomised trial will evaluate the effect of 177Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs PSMA 617 (Primary) ; Cabazitaxel
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TheraP
- 10 Nov 2017 New trial record
- 06 Nov 2017 According to Endocyte media release, this trial is planned to initiate in Dec 2017.